NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
19
Data completeness
5/8 — Partial
LUMIFY (brimonidine tartrate) by Bausch + Lomb is alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Approved for ocular hypertension, glaucoma, ocular redness. First approved in 2017.
Drug data last refreshed 19h ago
Mechanism of Action
alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
Indications (3)
Worked on LUMIFY at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.